BR100 Increased By (0.05%)
BR30 Increased By (0.49%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.39%)
AGHA 6.44 Increased By ▲ 0.12 (1.9%)
BECO 4.37 Increased By ▲ 0.10 (2.34%)
BML 62.50 Increased By ▲ 0.05 (0.08%)
BOP 31.43 Increased By ▲ 0.20 (0.64%)
CNERGY 11.67 Increased By ▲ 0.08 (0.69%)
CSIL 5.84 Increased By ▲ 0.12 (2.1%)
FCCL 60.60 Decreased By ▼ -0.94 (-1.53%)
FFL 14.83 Decreased By ▼ -0.19 (-1.26%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.66 Decreased By ▼ -0.02 (-0.08%)
MLCF 103.02 Decreased By ▼ -1.06 (-1.02%)
NBP 173.00 Decreased By ▼ -2.28 (-1.3%)
NCPL 52.30 Decreased By ▼ -0.47 (-0.89%)
NPL 53.85 Decreased By ▼ -0.27 (-0.5%)
OGDC 316.60 Increased By ▲ 3.21 (1.02%)
PACE 9.28 Increased By ▲ 0.08 (0.87%)
PAEL 35.60 Decreased By ▼ -0.20 (-0.56%)
PIBTL 13.68 Increased By ▲ 0.21 (1.56%)
PPL 226.12 Increased By ▲ 4.31 (1.94%)
PRL 80.40 Increased By ▲ 1.32 (1.67%)
PTC 46.87 Increased By ▲ 0.02 (0.04%)
SSGC 23.80 Decreased By ▼ -0.07 (-0.29%)
TBL 9.29 Decreased By ▼ -0.02 (-0.21%)
TELE 7.57 Increased By ▲ 0.18 (2.44%)
TPL 24.63 Decreased By ▼ -0.48 (-1.91%)
TPLP 12.85 Increased By ▲ 0.34 (2.72%)
TREET 25.89 Decreased By ▼ -0.36 (-1.37%)
TRG 53.30 Decreased By ▼ -0.14 (-0.26%)
World

Poorer countries to get 120 million $5 coronavirus tests, WHO says

  • The wider availability of quick, reliable and inexpensive testing will help 133 countries to track infections and contain the spread, closing the gap with wealthy ones.
  • The tests were currently priced at a maximum of $5 each but were expected to become cheaper.
Published Updated
By

GENEVA/LONDON: Some 120 million rapid diagnostic tests for coronavirus will be made available to low- and middle-income countries at a maximum of $5 each, the World Health Organization (WHO) said on Monday.

The wider availability of quick, reliable and inexpensive testing will help 133 countries to track infections and contain the spread, closing the gap with wealthy ones, it said.

WHO Director General Tedros Adhanom Ghebreyesus said the manufacturers Abbott and SD Biosensor had agreed with the Bill & Melinda Gates Foundation to "make 120 million of these new, highly portable and easy-to-use rapid COVID-19 diagnostic tests available over a period of six months".

He told a news conference in Geneva the tests were currently priced at a maximum of $5 each but were expected to become cheaper.

"This will enable the expansion of testing, particularly in hard-to-reach areas that do not have laboratory facilities or enough trained health workers to carry out tests," Tedros said.

"This is a vital addition to the testing capacity and especially important in areas of high transmission."

Catharina Boehme, chief executive officer of the Foundation for Innovative New Diagnostics (FIND), a Geneva-based non-profit organisation in the project, said the deal was a "major milestone" as it was urgent to increase testing in poorer countries.

"It is our first line of defence, critical for countries to track, trace and isolate to stop the spread of the virus and to ensure that we are not flying blind," she said.

"We now have two high-quality tests which are the first in a series that are being developed and assessed by WHO for emergency use listing," she said.

The antigen tests - which don't require a laboratory - provide reliable results in just 15 minutes rather than hours or days and will help expand testing, Boehme said, adding: "The tests are as simple to use as pregnancy tests."

The Global Fund to Fight AIDS, Tuberculosis and Malaria - another Geneva-based group - was providing an initial $50 million to the procurement fund and the first orders were expected to be placed this week, she said.

Maria Van Kerkhove, WHO technical lead on COVID-19, said that more tests were undergoing evaluation and would come online.

They would be particularly useful in remote settings and to investigate clusters quickly and bring them under control and in areas with widespread community transmission.

"This will be really, really helpful for communities and countries to be able to know where is the virus and who is infected with the virus," she said.

Comments

Comments are closed for this article.